Last reviewed · How we verify
NCT02880644: HERMES
Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept
trial in Retinal Vein Occlusion in 65 participants. Completed in 30 November 2022.
30 November 2022
Quick facts
| Lead sponsor | Centre Hospitalier Intercommunal Creteil |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 65 |
| Start date | 26 January 2017 |
| Primary completion | 30 November 2022 |
| Estimated completion | 30 November 2022 |
| Sites | 9 locations across France |
Conditions studied
- Retinal Vein Occlusion — all drugs for Retinal Vein Occlusion →
Sponsor
Centre Hospitalier Intercommunal Creteil
Who can join
Adults 18 to 100, any sex, with Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In patients with macular edema secondary to CRVO, Aflibercept demonstrated efficacy and safety in 2 parallel trials, interventional phase III studies, COPERNICUS study performed in United States and GALILEO study performed in Europe and Asia/Pacific. With the project of Hermes Study, the first observational study conducted in France in patients with CRVO and treated with aflibercept, we would like to evaluate in real life the monitoring and the use of Aflibercept. The primary objective of this study will also be based on anatomic outcomes. The evolution of retinal ischemia and the degree of non-retinal perfusion will be particularly evaluated by using ultra wide field angiography technology.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02880644
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinal Vein Occlusion
Currently open trials in the same condition.
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06439576 — Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Relat · recruiting
- NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting
- NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting
- NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting
Other Centre Hospitalier Intercommunal Creteil trials
Trials by the same sponsor.
- NCT07493785 — Dexmedetomidine for Invasive Ventilation In the NEOnate · Phase 2, PHASE3 · not yet recruiting
- NCT07513051 — DIaphragmatic Swing According to Cpap Flow Output in NEOnates (DISCONEO) · NA · not yet recruiting
- NCT07455942 — Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer · not yet recruiting
- NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting
- NCT06339450 — Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02880644 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Intercommunal Creteil
- Last refreshed: 29 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02880644.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing